CNS Pharmaceuticals, Inc.
NASDAQ: CNSP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rami Levin
- Employees
- 4
- Headquarters
- Houston, United States
- IPO year
- 2019
- Market cap
- $2.4M
- Website
- https://www.cnspharma.com
Loading CNSP…
Loading profile data…Frequently asked questions about CNSP
What does CNS Pharmaceuticals, Inc. (CNSP) do?
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment f...
Where does CNSP trade?
CNS Pharmaceuticals, Inc. (CNSP) trades on the NASDAQ Capital Market.
What sector is CNSP in?
CNS Pharmaceuticals, Inc. (CNSP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CNS Pharmaceuticals, Inc.?
Rami Levin is the chief executive officer of CNS Pharmaceuticals, Inc. (CNSP).
Where is CNS Pharmaceuticals, Inc. headquartered?
CNS Pharmaceuticals, Inc. is headquartered in United States.
Does CNSP pay a dividend?
CNS Pharmaceuticals, Inc. (CNSP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CNSP go public?
CNS Pharmaceuticals, Inc. (CNSP) completed its initial public offering in 2019.